[1]
Armstrong, A.W., Lebwohl, M., Warren, R.B., Sofen, H., Imafuku, S., Ohtsuki, M., Spelman, L., Passeron, T., Papp, K.A., Kisa, R.M., Berger, V., Vritzali, E., Hoyt, K., Colombo, M.J., Banerjee, S., Strober, B., Thaçi, D. and Blauvelt, A. 2023. Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s240. DOI:https://doi.org/10.25251/skin.7.supp.240.